Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Pharma - Formulators
  4. /Natco Pharma Ltd
MomentumDeep Value

Natco Pharma Ltd: Stock Analysis & Fundamentals

Updated this week

Natco Pharma Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 11.3. ROE: 16.9%. This stock is not currently in the Nifty 500 momentum outperformers list.

Natco Pharma Ltd Key Facts

What's Happening

💪Debt reduced 63% YoY — balance sheet strengthening
🌐FII stake decreased 3.4% this quarter

Key Risks

1. Regulatory
HIGH
2. Regulatory
MEDIUM
3. Geopolitical
MEDIUM

Key Numbers

Current Price
₹894
Dividend Yield
0.67%
Market Cap
16.0K Cr
Valuation
N/A

What Are the Key Risks for Natco Pharma Ltd?

Earnings deceleration risks from management commentary

Regulatory

HIGH

Trigger: If DCGI approval is delayed materially beyond Q1 FY27, the ₹80-90 Cr semaglutide contribution and 20%+ domestic growth guidance are at risk

Monitor: regulatory

Regulatory

MEDIUM

Trigger: Exclusivity-period PAT margins (40-50%) vs base-business margins (27-32%) represent a structural volatility in earnings quality

Monitor: regulatory

Geopolitical

MEDIUM

Trigger: South Africa's ZAR/INR exchange rate volatility and sub-Saharan Africa's macroeconomic fragility could reduce reported PAT contribution in INR terms

Monitor: geopolitical

Regulatory

LOW

Trigger: NCLT and competition authority timelines are uncertain; the demerger value-unlock thesis is time-sensitive for FY27 stock performance

Monitor: regulatory

What Is Natco Pharma Ltd's Management Saying?

Key quotes from recent conference calls

“We expect to be in the first wave of generic launches in India post-March 2026. DCGI approval is still pending as of the call date [Risk (regulatory): HIGH]”
“EBITDA margin contracted year-on-year as the base included partial Revlimid exclusivity premium in Q4 FY25. Pomalidomide exclusivity launched in March 2026 should partially offset Revlimid expiry impact through Q1 FY27 [Risk (regulatory): MEDIUM]”
“The acquisition, valued at approximately $226 million (R4 billion), was completed on November 11, 2025. Adcock Ingram operates across South Africa, Sub-Saharan Africa, India, and select international markets [Risk (geopolitical): MEDIUM]”
“The demerger is expected to be completed by October-November 2026, subject to NCLT and regulatory approvals [Risk (regulatory): LOW]”

The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.

Other Top Pharma - Formulators Stocks Beating Nifty 500

Cipla Ltd
Weak
+8.1%
Zydus Lifesciences Ltd
Strong • 6w streak
+14.3%
Mankind Pharma Ltd
Average
+14.0%
Aurobindo Pharma Ltd
Average • 12w streak
+11.3%
Emcure Pharmaceuticals Ltd
Average • 12w streak
+10.4%
← Back to Pharma - FormulatorsDashboard

Frequently Asked Questions: Natco Pharma Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Natco Pharma Ltd's latest quarterly results?

Natco Pharma Ltd's latest quarterly results (Mar 2026) show

  • PAT Growth YoY: -33.7%
  • Revenue Growth YoY: -39.5%
  • Operating Margin: 17.0%

What is Natco Pharma Ltd's current PE ratio?

Natco Pharma Ltd's current PE ratio is 11.3x.

  • Current PE: 11.3x
  • Market Cap: 16.0K Cr
  • Dividend Yield: 0.67%

What is Natco Pharma Ltd's price-to-book ratio?

Natco Pharma Ltd's price-to-book ratio is 1.7x.

  • Price-to-Book (P/B): 1.7x
  • Book Value per Share: ₹515
  • Current Price: ₹894

Is Natco Pharma Ltd a fundamentally strong company?

Natco Pharma Ltd's fundamental strength based on key financial ratios

  • Return on Capital (ROCE): 17.0%

Is Natco Pharma Ltd debt free?

Natco Pharma Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹714 Cr

What is Natco Pharma Ltd's return on equity (ROE) and ROCE?

Natco Pharma Ltd's return ratios over recent years

  • FY2024: ROCE 30.0%
  • FY2025: ROCE 33.0%
  • FY2026: ROCE 17.0%

Is Natco Pharma Ltd's cash flow positive?

Natco Pharma Ltd's operating cash flow is positive (FY2026).

  • Cash from Operations (CFO): ₹2,000 Cr
  • Free Cash Flow (FCF): ₹-314 Cr
  • CFO/PAT Ratio: 125% (strong cash conversion)

What is Natco Pharma Ltd's dividend yield?

Natco Pharma Ltd's current dividend yield is 0.67%.

  • Dividend Yield: 0.67%
  • Current Price: ₹894

Who holds Natco Pharma Ltd shares — promoters, FII, DII?

Natco Pharma Ltd's shareholding pattern (Mar 2026)

  • Promoters: 49.4%
  • FII (Foreign): 17.4%
  • DII (Domestic): 5.5%
  • Public: 27.7%

Is promoter holding increasing or decreasing in Natco Pharma Ltd?

Natco Pharma Ltd's promoter holding has decreased recently.

  • Current Promoter Holding: 49.4% (Mar 2026)
  • Previous Quarter: 49.5% (Dec 2025)
  • Change: -0.07% (decreasing — worth monitoring)

Is Natco Pharma Ltd a new momentum entry or an established outperformer?

Natco Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

What are the key risks in Natco Pharma Ltd?

Natco Pharma Ltd has 4 key risks worth monitoring

  • [HIGH] Regulatory — If DCGI approval is delayed materially beyond Q1 FY27, the ₹80-90 Cr semaglutide contribution and 20%+ domestic growth guidance are at risk
  • [MEDIUM] Regulatory — Exclusivity-period PAT margins (40-50%) vs base-business margins (27-32%) represent a structural volatility in earnings quality
  • [MEDIUM] Geopolitical — South Africa's ZAR/INR exchange rate volatility and sub-Saharan Africa's macroeconomic fragility could reduce reported PAT contribution in INR terms
  • [LOW] Regulatory — NCLT and competition authority timelines are uncertain; the demerger value-unlock thesis is time-sensitive for FY27 stock performance

What did Natco Pharma Ltd's management say in the latest earnings call?

In Q4 FY26, Natco Pharma Ltd's management highlighted

  • "We expect to be in the first wave of generic launches in India post-March 2026. DCGI approval is still pending as of the call date [Risk (regulatory)..."
  • "EBITDA margin contracted year-on-year as the base included partial Revlimid exclusivity premium in Q4 FY25. Pomalidomide exclusivity launched in March..."
  • "The acquisition, valued at approximately $226 million (R4 billion), was completed on November 11, 2025. Adcock Ingram operates across South Africa, Su..."

Is Natco Pharma Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Natco Pharma Ltd may be worth studying

  • Cash flow is positive — CFO ₹2,000 Cr

What is the investment thesis for Natco Pharma Ltd?

Natco Pharma Ltd investment thesis summary:

Risk Factors (Bear Case)

  • Key risk: Regulatory

What is the future outlook for Natco Pharma Ltd?

Natco Pharma Ltd's forward outlook based on current data signals

  • Key Risk: Regulatory

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.